Zimmer Biomet (NYSE:ZBH) Issues Quarterly Earnings Results

Zimmer Biomet (NYSE:ZBH) released its quarterly earnings data on Wednesday. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $2.01 by $0.06, FiscalAI reports. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same period last year, the firm posted $2.07 earnings per share. Zimmer Biomet’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet updated its FY 2026 guidance to 8.470-8.590 EPS.

Here are the key takeaways from Zimmer Biomet’s conference call:

• Positive Sentiment: Zimmer Biomet reported Q2 net sales of $2.177 billion, up 4.0% organically at constant currency, exceeding expectations; U.S. organic growth was 4.6%, led by hips, technology, and higher-growth S.E.T. businesses.
• Positive Sentiment: The company raised its 2026 organic revenue growth outlook to 2.25%-3.25% from 1%-3% and adjusted EPS guidance to $8.47-$8.59; reported sales growth guidance increased to 3.9%-4.9%.
• Positive Sentiment: New products and technology are gaining traction, including the Z1 hip stem, HAMMR, OrthoGrid, iodine-coated hips in Japan, and ROSA Shoulder; technology sales grew 21.5% overall and more than 50% in the U.S.
• Neutral Sentiment: The U.S. sales-force transformation is progressing ahead of expectations, but Zimmer Biomet plans to continue investing in specialized commercial capabilities through 2027, putting pressure on margins; Q2 adjusted operating margin declined 210 basis points to 25.7%.
• Positive Sentiment: Operating cash flow rose 18% to $448 million and free cash flow increased 24% to $308 million; the company plans to repurchase up to $1 billion of shares in 2026, including $500 million already repurchased in the first half.

Zimmer Biomet Trading Down 1.8%

Shares of NYSE:ZBH traded down $1.74 during trading hours on Thursday, hitting $96.42. 948,839 shares of the company’s stock traded hands, compared to its average volume of 2,323,652. The business has a fifty day moving average price of $89.61 and a 200-day moving average price of $90.02. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The firm has a market capitalization of $18.65 billion, a P/E ratio of 25.00, a price-to-earnings-growth ratio of 2.82 and a beta of 0.45.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were paid a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Royal Bank Of Canada restated an “outperform” rating and issued a $110.00 price target on shares of Zimmer Biomet in a research note on Thursday. Stifel Nicolaus upped their target price on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday. Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a research note on Wednesday, April 29th. Zacks Research lowered Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, July 27th. Finally, Wells Fargo & Company lowered their price objective on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average target price of $103.30.

Key Stories Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q2 results exceeded expectations. Zimmer Biomet reported adjusted earnings of $2.07 per share, ahead of the $2.01 consensus estimate, while revenue rose 4.8% year over year to $2.177 billion, topping the $2.13 billion forecast. Zimmer Biomet Announces Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 guidance was updated. Management guided to adjusted EPS of $8.47–$8.59 and revenue of approximately $8.6 billion, broadly supporting or slightly improving Wall Street expectations. Reported diluted EPS increased 33.8% to $1.03. Zimmer Biomet raises guidance on Q2 beats
• Positive Sentiment: Stifel became more bullish. The firm raised its price target from $105 to $110 and assigned a “Buy” rating, implying meaningful potential appreciation from recent trading levels. Benzinga analyst update
• Neutral Sentiment: Valuation commentary is supportive but not a major catalyst. Zacks identified ZBH as a strong value stock based on its Style Scores, although the article provides no new company-specific operating information. Why Zimmer Biomet Is a Strong Value Stock
• Negative Sentiment: Margin pressure remains a concern. Coverage noted that the quarterly beat occurred despite pressure on adjusted margins, and adjusted EPS was unchanged from the prior-year period. Investors may therefore want evidence that revenue growth can translate into stronger profitability. ZBH Q2 Earnings Beat and 2026 View Raised

Insider Buying and Selling

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.28% of the stock is owned by corporate insiders.

Institutional Trading of Zimmer Biomet

Several hedge funds have recently modified their holdings of the company. DV Equities LLC purchased a new stake in Zimmer Biomet in the fourth quarter valued at approximately $25,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth $31,000. Headlands Technologies LLC acquired a new stake in shares of Zimmer Biomet during the 2nd quarter worth about $37,000. EFG International AG acquired a new position in Zimmer Biomet in the fourth quarter valued at about $55,000. Finally, Mpwm Advisory Solutions LLC purchased a new position in shares of Zimmer Biomet in the third quarter valued at approximately $65,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.